Efficacy and toxicities of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for unresectable pancreatic cancer: a systematic review and meta-analysis
Objective Modified FOLFIRINOX (mFFX) and gemcitabine plus nab-paclitaxel (GnP) are both recommended as standard first-line regimens for unresectable pancreatic cancer (PC). However, direct head-to-head comparative evidence remains scarce, and prior studies have largely failed to distinguish mFFX from standard FOLFIRINO...